fashion -WSS

fashion

author：comprehensive 2025-09-02 11:49:02 - browse：2

This image provided by Eisai in January 2023 shows vials and packaging for their medication, Leqembi. — Illustration: Alex Hogan/STAT; Photo: Eisai via AP

Seven months after US drug regulators fully approved Biogen’s treatment for Alzheimer’s disease, only about 2,000 patients are taking the medicine nationwide, the company said Tuesday.

Biogen’s chief executive, Christopher A. Viehbacher, said as the firm released fourth-quarter earnings that he had expected the slow uptake and sees considerable demand for the medication. He told reporters that 3,800 patients with early-stage Alzheimer’s have signed up on multiple registries to receive the drug, called Leqembi, as of last month.

Before patients can get the drug, which costs $26,500-a-year, they must undergo a brain scan or a spinal tap to confirm that they have build-up of deposits of a sticky toxic protein called beta-amyloid that is a hallmark of the disease.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： The cancer drug shortage isn’t new — and neither are the solutions
Next article： President Biden's budget: Here's what you might have missed

Wikipedia

WSS

Profiling embryos to choose those with higher IQs is almost a reality

FDA advisers back CAR

FDA early review: GLP

Readout Newsletter: CAR

Why depression after traumatic brain injury is distinct

Gene therapy denied for Afghan refugee whose father aided U.S.

focus

fashion

focus

At least 13 dead in Texas as scorching temps continue

Readout Newsletter: CAR

Cancer drug shortages should be causing more outrage

Why depression after traumatic brain injury is distinct

Jerome Adams on the need for new antivirals for Covid

John Green on his newest strategy for fighting tuberculosis

Novavax promises a turnaround & Lilly roils the obesity market

Boston Scientific acquires urology company Axonics for $3.7 billion

As demand for Covid shots wanes, Moderna seeks its next success

Nonprofit, backed by Microsoft, to certify AI tools in health care

hotspot

American taxpayers paid $1.8 trillion in health care costs in 2022

Arena BioWorks launches in Cambridge to speed drug discovery

Bayer exec: U.S. is key in reviving beleaguered pharma’s drug pipeline

Physician assistants need a new name. Here's what it should be

Pushing for an NIH office for post

Readout Newsletter: Bristol, Sangamo, Gilead, and more

Wikipedia

focus

leisure time

focus